MBM-01 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 65 | Primary immunodeficiency | 1 |
65. Primary immunodeficiency
Clinical trials : 482 / Drugs : 653 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 212
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04887311 (ClinicalTrials.gov) | July 2021 | 5/5/2021 | MBM-01 (Tempol) for the Treatment of Ataxia Telangiectasia | An Open Label Study to Assess the Safety and Efficacy of MBM-01 for the Treatment of Ataxia Telangiectasia | Ataxia Telangiectasia Louis-Bar;Ataxia Telangiectasia in Children;Ataxia Telangiectasia | Drug: MBM-01 | Matrix Biomed, Inc. | The University of Texas Health Science Center, Houston | Not yet recruiting | 4 Years | N/A | All | 20 | Phase 2 | United States |